Ftse Mib
34.525,35
-0,23%
DAX
18.671,24
-0,29%
S&P 500
5.321,41
0,25%
NASDAQ
16.832,62
0,00%
Bitcoin
69.936,35
-0,28%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NGM Biopharmaceuticals Inc (NGM) NGM Biopharmaceuticals Inc (NGM) Notizie

NGM

NGM Biopharmaceuticals (NGM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NGM
DataOraFonteTitoloSimboloCompagnia
05/04/202415:19GlobeNewswire Inc.NGM Bio Announces Closing of Tender OfferNASDAQ:NGMNGM Biopharmaceuticals Inc
19/03/202422:30GlobeNewswire Inc.NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
11/03/202421:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NGMNGM Biopharmaceuticals Inc
11/03/202421:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
11/03/202421:05GlobeNewswire Inc.NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NGMNGM Biopharmaceuticals Inc
08/03/202423:32Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:NGMNGM Biopharmaceuticals Inc
08/03/202423:21Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:NGMNGM Biopharmaceuticals Inc
26/02/202423:11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:NGMNGM Biopharmaceuticals Inc
26/02/202415:03GlobeNewswire Inc.NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPNASDAQ:NGMNGM Biopharmaceuticals Inc
20/02/202422:01GlobeNewswire Inc.NGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
15/02/202400:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NGMNGM Biopharmaceuticals Inc
19/01/202400:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
17/01/202422:47GlobeNewswire Inc.NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
09/01/202414:00GlobeNewswire Inc.NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet NeedNASDAQ:NGMNGM Biopharmaceuticals Inc
13/11/202315:45GlobeNewswire Inc.NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®NASDAQ:NGMNGM Biopharmaceuticals Inc
09/11/202300:13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
07/11/202322:05GlobeNewswire Inc.NGM Bio to Participate in Upcoming Investor ConferencesNASDAQ:NGMNGM Biopharmaceuticals Inc
02/11/202321:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NGMNGM Biopharmaceuticals Inc
02/11/202321:01GlobeNewswire Inc.NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:NGMNGM Biopharmaceuticals Inc
11/10/202322:05GlobeNewswire Inc.NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®NASDAQ:NGMNGM Biopharmaceuticals Inc
27/09/202314:30PR Newswire (US)Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and Accelerate the Development of Novel MedicinesNASDAQ:NGMNGM Biopharmaceuticals Inc
11/09/202322:01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:NGMNGM Biopharmaceuticals Inc
07/08/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NGMNGM Biopharmaceuticals Inc
04/08/202323:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NGMNGM Biopharmaceuticals Inc
04/08/202322:01Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:NGMNGM Biopharmaceuticals Inc
03/08/202322:01GlobeNewswire Inc.NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:NGMNGM Biopharmaceuticals Inc
08/06/202312:31Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:NGMNGM Biopharmaceuticals Inc
08/06/202312:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NGMNGM Biopharmaceuticals Inc
12/05/202323:55Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
08/05/202322:05GlobeNewswire Inc.NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023NASDAQ:NGMNGM Biopharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NGM

La tua Cronologia

EU
Q679S
Q679S
ASX
SZGN
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network